Sector News

Alexion appoints new senior VP for EMEAC region

February 6, 2018
Life sciences

Camillia HartvigAlexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.

She will lead the commercial activities of the regional function from Alexion’s EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.

Regarding her new role, Hartvig said: “I am delighted to join the great team in this region, that is a strategic pillar for Alexion accounting for more than a third of Alexion’s global business, and look forward to stewarding the company’s growth and development hire in the years ahead.”

Hartvig, who has more than 20 years’ experience in the pharmaceutical industry, has worked in a broad spectrum of companies, including AstraZeneca, Novartis and Allergan.

Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology.

She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.

Source: PMLive

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach